Search Results
Your search for ,had matches 18486 pages
Showing 7201 - 7250Addressing Discrimination and Bias in Medical Education
“As a medical student, I often felt marginalized from my medical community. I have been told that my name is ‘not American,’ fallen prey to being confused for support staff such as a janitor (even while wearing my white coat), and been asked questions like, ‘Where are you really from?’ or ‘How old...
Number of Hospitalizations May Be an Important Indicator of Survival for Patients With Head and Neck Cancer
Patients who were unexpectedly hospitalized for dehydration, fever, or other events while undergoing radiotherapy for head and neck cancer were at a higher risk for less favorable outcomes, according to a study published by Anurag K. Singh, MD, and colleagues in Oral Oncology. Researchers found...
Early Screening With MRI May Reduce Breast Cancer Mortality in Survivors of Childhood Cancer Treated With Chest Radiation
The early initiation—at age 25 to 30—of annual breast cancer screening with magnetic resonance imaging (MRI) with or without mammography may reduce breast cancer mortality by more than half in survivors of childhood cancer who had been previously exposed to chest radiation, according to a study by...
GI-Related Patient-Reported Outcomes in Individuals Receiving Chemoradiation for Anal Cancer
In a single-institution study reported in JCO Oncology Practice, Kouzy et al found that gastrointestinal (GI)-related patient-reported outcomes among those receiving chemoradiation for anal cancer improved vs baseline at 1 week after treatment initiation, were worse vs baseline at 5 weeks, but did...
Expert Point of View: Robert L. Coleman, MD
Discussant of the DESKTOP III and SOC1 trials, Robert L. Coleman, MD, of U.S. Oncology Research in Woodlands, Texas, congratulated the authors of both trials. He put these results in perspective with the GOG-0213 study, which did not show a survival benefit for secondary surgery. “There are general ...
Two Studies Report Secondary Surgery Extends Survival in Recurrent Ovarian Cancer
Two phase III trials provide support for secondary cytoreductive surgery in women with recurrent ovarian cancer, with the caveats that patient selection is key and the surgery should be performed at sites of excellence. The results of the DESKTOP III and SOC1 trials, both presented during the...
Post Hoc Analysis of Outcomes With Vandetanib for Progressive and Symptomatic Medullary Thyroid Cancer
As reported in the Journal of Clinical Oncology by Kreissl et al, a post hoc analysis of outcomes in the pivotal phase III ZETA trial has shown significantly improved progression-free survival with the multikinase inhibitor vandetanib vs placebo in a subgroup of patients with progressive and...
ESMO World GI: Third- or Later-Line Treatment With Infigratinib in Patients With Cholangiocarcinoma and FGFR2 Fusions
At the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2020 Virtual, Javle et al reported that third- and later-line treatment with the selective fibroblast growth factor receptor (FGFR) 1-3 inhibitor infigratinib resulted in a progression-free survival and...
Expert Point of View: Don S. Dizon, MD, FACP, FASCO
Commenting on the SOLO2 trial for The ASCO Post was Don S. Dizon, MD, FACP, FASCO, Director of Women’s Cancers at Lifespan Cancer Institute and Professor of Medicine at Brown University, Providence, Rhode Island. “It’s great to get an overall survival advantage from a PARP inhibitor study. Coming...
Longer-Term Results of Pivotal Study in Advanced Cutaneous Squamous Cell Carcinoma
New, longer-term data from a pivotal phase II trial in advanced cutaneous squamous cell carcinoma (CSCC), were presented during the ASCO20 Virtual Scientific Program and discussed during a poster discussion.1 Danny Rischin, MD, of the Peter MacCallum Cancer Centre, Victoria, Australia, presented...
PSMA-Targeted PET/CT Imaging May Be Useful in Biochemically Recurrent Prostate Cancer
Positron-emission tomography/computed tomography (PET/CT) imaging with the prostate-specific membrane antigen (PSMA)-targeted radiotracer fluorine F-18 DCFPyL (PyL) successfully identified areas of occult metastasis in men with biochemically recurrent metastatic castration-resistant prostate...
Savolitinib vs Sunitinib in MET-Driven Papillary Renal Cell Carcinoma
Targeting MET alterations with savolitinib appears to be a better strategy than sunitinib for patients with MET-driven papillary renal cell carcinoma, according to results of the open-label, randomized, phase III SAVOIR trial.1 Patients with MET-driven metastatic papillary renal cell carcinoma...
Final Analysis of Phase II Trial in Recurrent Platinum-Sensitive Ovarian Cancer
In a poster presentation at the ASCO20 Virtual Scientific Program, Mansoor Raza Mirza, MD, of the the Department of Oncology, Rigshopitalet, Copenhagen University Hospital, Denmark, and colleagues reported the final analysis of the phase II NSGO-AVANOVA2/ENGOT-OV24 trial comparing the...
Maintenance Olaparib Shows Overall Survival Benefit in Ovarian Cancer
In the final, preplanned, overall survival analysis in the randomized phase III SOLO2/ENGOT-ov211 trial, maintenance treatment with the PARP inhibitor olaparib extended overall survival by an unprecedented 12.9 months, compared with placebo. This marks the first time that overall survival has been...
Avelumab Shown Effective in Rare Chemotherapy-Resistant Gynecologic Tumor in TROPHIMMUN Trial
Almost 50% of patients resistant to single-agent chemotherapy responded in the first trial of immunotherapy for gestational trophoblastic tumors, reported French investigators in an abstract presented during the ASCO20 Virtual Scientific Program.1 Benoit You, MD, PhD, of Lyon University Hospital,...
For Patients With Early-Stage Cervical Cancer, Sentinel Lymph Node Biopsy Declared Oncologically Safe
Bilateral pelvic lymphadenectomy represents the current “gold standard” for lymph node staging in cervical cancer—but an assessment of disease-free and disease-specific survival among patients with early-stage cervical cancer determined that sentinel lymph node biopsy alone is a valid standard of...
Alpelisib Deemed Effective in Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor
The phase II BYLieve trial indicates the effectiveness of the PIK3CA inhibitor alpelisib in patients with PIK3CA-positive, hormone receptor–positive/HER2-negative advanced breast cancer previously treated with a cyclin-dependent kinase (CDK) 4/6 inhibitor plus an aromatase inhibitor. These results...
Study Indicates Effectiveness of Tucatinib Combination in Previously Treated HER2-Positive Metastatic Breast Cancer With Brain Metastases
Tucatinib, a small-molecule tyrosine kinase inhibitor that is highly selective for HER2, plus trastuzumab/capecitabine significantly improved central nervous system (CNS) progression-free survival, overall survival, and intracranial response rate vs placebo plus trastuzumab/capecitabine, as shown...
First-Line Nivolumab Plus Ipilimumab Shows Activity in NSCLC, With or Without Chemotherapy
Advanced non–small cell lung cancer (NSCLC) in patients whose tumors have no EGFR or ALK alterations poses a particular challenge in terms of first-line therapy. The use of nivolumab plus ipilimumab as well as nivolumab/ipilimumab plus two cycles of chemotherapy, respectively, as first-line therapy ...
Belantamab Mafodotin Shows Activity in Relapsed or Refractory Myeloma
Treatment of relapsed or refractory multiple myeloma yielded responses with the antibody-drug conjugate belantamab mafodotin, both as a single agent and in combination with bortezomib and dexamethasone. Two reports from the DREAMM team expanded on these findings at the ASCO20 Virtual Scientific...
No Survival Benefit from Local Therapy in de Novo Metastatic Breast Cancer Study
Results of the phase III E2108 study indicate that surgery and radiotherapy given after systemic treatment afforded no additional survival benefit among women with newly diagnosed metastatic breast cancer. The practice may, however, reduce locoregional progression of disease, according to a report...
Outcomes in Newly Diagnosed Multiple Myeloma Unimproved by Carfilzomib Triplet vs Standard Bortezomib-Based Regimen
No superior efficacy was shown with the combination of carfilzomib, lenalidomide, and dexamethasone (KRd) in newly treated patients with standard- and intermediate-risk multiple myeloma who are not slated for immediate autologous stem cell transplantation (ASCT), compared with the standard of care: ...
Rates of Progression-Free Survival in MSI-H/dMMR Metastatic Colorectal Cancer Doubled by Pembrolizumab
Upfront treatment with immunotherapy not only improved results in a subset of patients with metastatic colorectal cancer, it doubled the rates of median progression-free survival. These findings—the first of their kind—arose from the interim analysis of the randomized open-label phase III...
Advanced Bladder Cancer Survival Improved With Maintenance Avelumab
According to an interim analysis of the phase III JAVELIN Bladder 100 trial, rates of survival among patients with advanced urothelial carcinoma who did not progress on first-line platinum-based chemotherapy were significantly prolonged by maintenance therapy with avelumab and best supportive care...
Expert Point of View: Lecia V. Sequist, MD
Lecia V. Sequist, MD, who was not involved in the ADAURA study, said this could be a practice-changing study. Dr. Sequist is the Landry Family Professor of Medicine at Harvard Medical School and Director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital....
Conference Highlights From the ASCO20 Virtual Scientific Program
The global outbreak of the COVID-19 pandemic forced many cancer societies, including ASCO, to cancel their in-person meetings this year and instead present the latest advancements and new approaches in oncology care via a virtual platform. For the first time in its 56-year history, the ASCO Annual...
Personalized RNA-Based Vaccine/Atezolizumab Combination Produced Immune Response in Most Patients With Advanced Tumors
AN APPROACH using an RNA-based personalized cancer vaccine called RO7198457 in combination with the PD-L1 inhibitor atezolizumab has shown a preliminary benefit, according to an early study in patients with advanced solid tumors. The novel combination was well tolerated, and 8% of patients showed a ...
Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
In the phase IIb SADAL trial reported in The Lancet Haematology, Kalakonda et al found that the oral nuclear export inhibitor selinexor produced durable responses in patients with relapsed or refractory diffuse large B-cell lymphoma. Findings in the trial supported the recent accelerated U.S. Food...
Phase I Trial of Berzosertib Alone or Combined With Carboplatin in Advanced Solid Tumors
In a phase I trial reported in the Journal of Clinical Oncology, Timothy A. Yap, MBBS, PhD, FRCP, and colleagues identified recommended phase II doses of the first-in-class ATR (ataxia telangiectasia and Rad3–related) kinase inhibitor berzosertib alone and in combination with carboplatin and found...
Can Use of an Algorithm Improve the Accuracy and Efficiency of Cervical Cancer Screening?
In a new study published by Wentzensen et al in the Journal of the National Cancer Institute, a computer algorithm improved the accuracy and efficiency of cervical cancer screening compared with cytology (Papanicolaou [Pap] test), the current standard for follow-up of women who test positive in...
Adding Cyclophosphamide to Bortezomib/Dexamethasone in Patients With Multiple Myeloma and Acute Kidney Injury From Cast Nephropathy
In a French trial reported in the Journal of Clinical Oncology, Bridoux et al found adding cyclophosphamide to bortezomib/dexamethasone offered no benefit for renal recovery of patients with multiple myeloma and initial cast nephropathy not requiring dialysis. Study Details In the multicenter...
Patient Factors Associated With Lack of Provider Recommendation for HPV Vaccination in Young Cancer Survivors
In a study reported in the Journal of Clinical Oncology, York et al found that perceived lack of insurance coverage for human papillomavirus (HPV) vaccine, male sex, and decreased parent-survivor communication regarding HPV vaccination were among the factors associated with an increased likelihood...
FDA Pipeline: Agents for the Treatment of Prostate and Pancreatic Cancers, Marginal Zone Lymphoma
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to relugolix for the treatment of advanced prostate cancer; Fast Track designation to a radioimmunotherapeutic treatment for marginal zone lymphoma; and Orphan Drug designation to a novel monoclonal antibody for...
Personalized RNA-Based Vaccine/Atezolizumab Combination Produced Immune Response in Most Patients With Advanced Tumors
AN APPROACH using an RNA-based personalized cancer vaccine called RO7198457 in combination with the PD-L1 inhibitor atezolizumab has shown a preliminary benefit, according to an early study in patients with advanced solid tumors. The novel combination was well tolerated, and 8% of patients showed a ...
Can Use of an Algorithm Improve the Accuracy and Efficiency of Cervical Cancer Screening?
In a new study published by Wentzensen et al in the Journal of the National Cancer Institute, a computer algorithm improved the accuracy and efficiency of cervical cancer screening compared with cytology (Papanicolaou [Pap] test), the current standard for follow-up of women who test positive in...
Phase I Trial of Berzosertib Alone or Combined With Carboplatin in Advanced Solid Tumors
In a phase I trial reported in the Journal of Clinical Oncology, Timothy A. Yap, MBBS, PhD, FRCP, and colleagues identified recommended phase II doses of the first-in-class ATR (ataxia telangiectasia and Rad3–related) kinase inhibitor berzosertib alone and in combination with carboplatin and found...
Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
In the phase IIb SADAL trial reported in The Lancet Haematology, Kalakonda et al found that the oral nuclear export inhibitor selinexor produced durable responses in patients with relapsed or refractory diffuse large B-cell lymphoma. Findings in the trial supported the recent accelerated U.S. Food...
Third- or Later-Line Treatment With Infigratinib in Patients With Cholangiocarcinoma and FGR2 Fusions
At the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2020 Virtual, Javle et al reported that third- and later-line treatment with the selective fibroblast growth factor receptor (FGFR) 1–3 inhibitor infigratinib resulted in a progression-free survival and...
Study Supports Pembrolizumab Plus Axitinib in Previously Untreated Advanced Renal Cell Carcinoma
Extended analysis of the phase III KEYNOTE-426 study upholds pembrolizumab plus axitinib as a preferred front-line regimen over sunitinib in patients with advanced sporadic renal cell carcinoma.1 These updated results were presented at the ASCO20 Virtual Scientific Program by Elizabeth R. Plimack,...
Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Pancreatic Cancer Across Age Groups: Additional Analysis of the POLO Trial
According to an additional analysis from the POLO trial, safety of maintenance olaparib in patients with a germline BRCA1 and/or BRCA2 mutation and metastatic pancreatic cancer is consistent, irrespective of age. Patients aged ≥ 65 years derived long-term progression-free survival benefit and...
Risk of Breast Cancer Recurrence: Serum Detection of Nonadherence to Adjuvant Tamoxifen
In a French study reported in the Journal of Clinical Oncology, Pistilli et al found that serum detection of nonadherence to adjuvant tamoxifen therapy was common and was associated with poorer distant disease-free survival among premenopausal women with breast cancer. Biochemical nonadherence was...
A Visiting Resident Oncologist’s Training During the COVID-19 Pandemic
A visiting away elective is a resident’s designated time to visit another academic program to foster the growth of medical knowledge through patient care from the perspective of another health-care system and educational experience. The time dedicated to make this dream happen is grueling. First is ...
Ursodeoxycholic Acid for Preventing Gallstones After Gastrectomy for Gastric Cancer
In a Korean trial reported in JAMA Surgery, Lee et al found that treatment with ursodeoxycholic acid was successful in preventing gallstone formation in patients who had undergone gastrectomy for gastric cancer. Study Details In the multicenter double-blind trial, 465 evaluable patients undergoing...
FDA Approves Maintenance Avelumab for the Treatment of Advanced Urothelial Carcinoma
On June 30, the U.S. Food and Drug Administration (FDA) approved avelumab (Bavencio) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy. JAVELIN Bladder 100 Efficacy of avelumab...
PICOS Score May Help Identify Patients With Brain Metastases at Risk of VTE
In a study published by Wolpert et al in the European Journal of Cancer, venous thromboembolic events (VTE) were reported in 12% of a cohort of patients with cancer that had metastasized to the brain. Researchers identified thrombogenicity of primary tumor, immobilization, chemotherapy, obesity,...
Addition of an ATR Inhibitor to Gemcitabine in Platinum-Resistant High-Grade Serous Ovarian Cancer
As reported in The Lancet Oncology by Panagiotis A. Konstantinopoulos, MD, and colleagues, a phase II trial has shown significantly prolonged progression-free survival with the addition of the ATR (ataxia telangiectasia and Rad3–related) kinase inhibitor berzosertib to gemcitabine in women with...
Addition of First-Line Atezolizumab to Vemurafenib and Cobimetinib in Patients With Unresectable Advanced BRAF V600–Mutant Melanoma
As reported in The Lancet by Gutzmer et al, the phase III IMspire150 trial has shown that the addition of atezolizumab to BRAF and MEK inhibitor therapy with vemurafenib and cobimetinib improved progression-free survival in first-line treatment of patients with unresectable BRAF V600–mutant...
Novel Androgen-Deprivation Therapy With Relugolix Causes Fewer Cardiac Events Than Leuprolide in Advanced Prostate Cancer
Men with prostate cancer on androgen-deprivation therapy are usually treated with leuprolide, a long-acting injectable luteinizing hormone-releasing hormone (LHRH) agonist requiring an every-3-month injection, but it may be possible for ADT to be delivered by a daily oral treatment, pending...
Biomarker Combination May Help Predict Response to Immunotherapy in Patients With Metastatic Urothelial Carcinoma
In patients with metastatic urothelial carcinoma, a novel combination of biomarkers from baseline tumor tissues was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors, according to findings published by Goswami et al in Science...
Mortality Risk in Patients With COVID-19 and Thoracic Malignancies: Initial Report From the TERAVOLT Registry Study
As reported in The Lancet Oncology by Marina C. Garassino, MD, and colleagues, initial findings from the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry study have identified potential factors associated with increased risk of mortality in patients infected with COVID-19...
